tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NTLA Stock Latest News

Intellia Therapeutics price target lowered to $29 from $31 at Citi
The FlyIntellia Therapeutics price target lowered to $29 from $31 at Citi
5d ago
NTLA
Intellia Therapeutics reports Q1 EPS ($1.12), consensus ($1.38)
PremiumThe Fly
Intellia Therapeutics reports Q1 EPS ($1.12), consensus ($1.38)
6d ago
NTLA
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
PremiumPress Releases
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
6d ago
NTLA
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
PremiumPress Releases
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
13d ago
NTLA
Intellia Therapeutics to present updated data from Phase 1/2 study of NTLA-2002
PremiumThe Fly
Intellia Therapeutics to present updated data from Phase 1/2 study of NTLA-2002
16d ago
NTLA
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
PremiumPress ReleasesIntellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
16d ago
NTLA
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
18d ago
BEAM
MREO
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
26d ago
BHVN
CRBP
Intellia Therapeutics Welcomes New Principal Accounting Officer
PremiumCompany Announcements
Intellia Therapeutics Welcomes New Principal Accounting Officer
29d ago
8K
NTLA
Intellia Ends Gene Editing Deal with Regeneron Pharmaceuticals
PremiumCompany Announcements
Intellia Ends Gene Editing Deal with Regeneron Pharmaceuticals
2M ago
8K
NTLA
Intellia Therapeutics announces first patient dosed in Phase 3 MAGNITUDE study
PremiumThe Fly
Intellia Therapeutics announces first patient dosed in Phase 3 MAGNITUDE study
2M ago
NTLA
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
PremiumPress Releases
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
2M ago
NTLA
5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
PremiumMarket News5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
2M ago
AMLX
AXSM
Intellia Expands At-The-Market Offering Program with Jefferies
PremiumCompany Announcements
Intellia Expands At-The-Market Offering Program with Jefferies
3M ago
8K
NTLA
Intellia Therapeutics downgraded to Neutral from Buy at Goldman Sachs
PremiumThe Fly
Intellia Therapeutics downgraded to Neutral from Buy at Goldman Sachs
3M ago
NTLA
Intellia Therapeutics price target lowered to $64 from $78 at Guggenheim
PremiumThe Fly
Intellia Therapeutics price target lowered to $64 from $78 at Guggenheim
3M ago
NTLA
Intellia Therapeutics price target raised to $73 from $72 at Canaccord
PremiumThe Fly
Intellia Therapeutics price target raised to $73 from $72 at Canaccord
3M ago
NTLA
Intellia Therapeutics reports Q4 EPS ($1.46), consensus ($1.45)
PremiumThe Fly
Intellia Therapeutics reports Q4 EPS ($1.46), consensus ($1.45)
3M ago
NTLA
NTLA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
NTLA Upcoming Earnings Report: What to Expect?
3M ago
NTLA
Intellia Therapeutics price target lowered to $24 from $38 at Baird
PremiumThe FlyIntellia Therapeutics price target lowered to $24 from $38 at Baird
3M ago
ALNY
NTLA
Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
PremiumThe Fly
Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
3M ago
NTLA
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
PremiumPress Releases
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
3M ago
NTLA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >